JP2018537419A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018537419A5 JP2018537419A5 JP2018519918A JP2018519918A JP2018537419A5 JP 2018537419 A5 JP2018537419 A5 JP 2018537419A5 JP 2018519918 A JP2018519918 A JP 2018519918A JP 2018519918 A JP2018519918 A JP 2018519918A JP 2018537419 A5 JP2018537419 A5 JP 2018537419A5
- Authority
- JP
- Japan
- Prior art keywords
- sulfonamide
- alkyl
- methoxy
- membered
- benzene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 50
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 39
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 22
- -1 pyrrolidinylethyl Chemical group 0.000 claims 22
- 125000001072 heteroaryl group Chemical group 0.000 claims 17
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 16
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 13
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 12
- 125000005843 halogen group Chemical group 0.000 claims 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 10
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 8
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 7
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 7
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 7
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims 5
- 125000004414 alkyl thio group Chemical group 0.000 claims 5
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 4
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 claims 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000004193 piperazinyl group Chemical group 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 3
- 125000004750 (C1-C6) alkylaminosulfonyl group Chemical group 0.000 claims 2
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 2
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- PNDOJSCZIOOHBK-UHFFFAOYSA-N 2-methylsulfonyl-N-phenylmethoxybenzenesulfonamide Chemical compound C(C1=CC=CC=C1)ONS(=O)(=O)C1=C(C=CC=C1)S(=O)(=O)C PNDOJSCZIOOHBK-UHFFFAOYSA-N 0.000 claims 1
- RFGZGEQKMFEMJC-UHFFFAOYSA-N 3-chloro-N-methoxythiophene-2-sulfonamide Chemical compound CONS(=O)(=O)C1=C(Cl)C=CS1 RFGZGEQKMFEMJC-UHFFFAOYSA-N 0.000 claims 1
- UMLZTQJOUQYZLT-UHFFFAOYSA-N 3-chloro-N-phenylmethoxythiophene-2-sulfonamide Chemical compound C(C1=CC=CC=C1)ONS(=O)(=O)C=1SC=CC=1Cl UMLZTQJOUQYZLT-UHFFFAOYSA-N 0.000 claims 1
- SHCCWPMSCYOOER-UHFFFAOYSA-N 3-methylsulfonyl-N-phenylmethoxybenzenesulfonamide Chemical compound C(C1=CC=CC=C1)ONS(=O)(=O)C1=CC(=CC=C1)S(=O)(=O)C SHCCWPMSCYOOER-UHFFFAOYSA-N 0.000 claims 1
- AMHHEMCWOWOHMG-UHFFFAOYSA-N 4-chloro-2-(furan-2-ylmethylamino)-5-(phenylmethoxysulfamoyl)benzoic acid Chemical compound C(C1=CC=CC=C1)ONS(=O)(=O)C=1C(=CC(=C(C(=O)O)C=1)NCC=1OC=CC=1)Cl AMHHEMCWOWOHMG-UHFFFAOYSA-N 0.000 claims 1
- SQYVBUFJBBPFBX-UHFFFAOYSA-N 4-methyl-N-phenylmethoxypiperazine-1-sulfonamide Chemical compound C(C1=CC=CC=C1)ONS(=O)(=O)N1CCN(CC1)C SQYVBUFJBBPFBX-UHFFFAOYSA-N 0.000 claims 1
- RUOUBIPZASOFDG-UHFFFAOYSA-N 4-methylsulfonyl-N-phenylmethoxybenzenesulfonamide Chemical compound C(C1=CC=CC=C1)ONS(=O)(=O)C1=CC=C(C=C1)S(=O)(=O)C RUOUBIPZASOFDG-UHFFFAOYSA-N 0.000 claims 1
- UPEDNHLWANPTAU-UHFFFAOYSA-N 6-chloro-N-methoxy-1-benzofuran-2-sulfonamide Chemical compound ClC1=CC2=C(C=C(O2)S(=O)(=O)NOC)C=C1 UPEDNHLWANPTAU-UHFFFAOYSA-N 0.000 claims 1
- MEYUUSGXWQIYDC-UHFFFAOYSA-N 6-chloro-N-phenylmethoxy-1-benzofuran-2-sulfonamide Chemical compound C(C1=CC=CC=C1)ONS(=O)(=O)C=1OC2=C(C=1)C=CC(=C2)Cl MEYUUSGXWQIYDC-UHFFFAOYSA-N 0.000 claims 1
- BUJSQPPKRFWBCP-UHFFFAOYSA-N 6-methoxy-N-phenylmethoxy-1-benzofuran-2-sulfonamide Chemical compound C(C1=CC=CC=C1)ONS(=O)(=O)C=1OC2=C(C=1)C=CC(=C2)OC BUJSQPPKRFWBCP-UHFFFAOYSA-N 0.000 claims 1
- 206010007556 Cardiac failure acute Diseases 0.000 claims 1
- XVKDZKOOVQMNQK-UHFFFAOYSA-N N,6-dimethoxy-1-benzofuran-2-sulfonamide Chemical compound CONS(=O)(=O)C=1OC2=C(C=1)C=CC(=C2)OC XVKDZKOOVQMNQK-UHFFFAOYSA-N 0.000 claims 1
- OYXHMQCJFAOQSZ-UHFFFAOYSA-N N-(1,3-benzodioxol-5-ylmethoxy)-2-methylsulfonylbenzenesulfonamide Chemical compound CS(=O)(=O)c1ccccc1S(=O)(=O)NOCc1ccc2OCOc2c1 OYXHMQCJFAOQSZ-UHFFFAOYSA-N 0.000 claims 1
- QKIICPAQMAJJOA-UHFFFAOYSA-N N-(2,1,3-benzoxadiazol-5-ylmethoxy)-3-methylsulfonylbenzenesulfonamide Chemical compound CS(=O)(=O)c1cccc(c1)S(=O)(=O)NOCc1ccc2nonc2c1 QKIICPAQMAJJOA-UHFFFAOYSA-N 0.000 claims 1
- YLSZQONYSDMSGE-UHFFFAOYSA-N N-(pyridin-2-ylmethoxy)-1-benzofuran-2-sulfonamide Chemical compound N1=C(C=CC=C1)CONS(=O)(=O)C=1OC2=C(C=1)C=CC=C2 YLSZQONYSDMSGE-UHFFFAOYSA-N 0.000 claims 1
- OJBDVRJYOCVSMU-UHFFFAOYSA-N N-(pyridin-3-ylmethoxy)-1-benzofuran-2-sulfonamide Chemical compound N1=CC(=CC=C1)CONS(=O)(=O)C=1OC2=C(C=1)C=CC=C2 OJBDVRJYOCVSMU-UHFFFAOYSA-N 0.000 claims 1
- QASJGJWMXGUEKL-UHFFFAOYSA-N N-[(2-chlorophenyl)methoxy]-1-benzofuran-2-sulfonamide Chemical compound ClC1=C(C=CC=C1)CONS(=O)(=O)C=1OC2=C(C=1)C=CC=C2 QASJGJWMXGUEKL-UHFFFAOYSA-N 0.000 claims 1
- OIFXFVKTGVOGRR-UHFFFAOYSA-N N-[(2-chlorophenyl)methoxy]-2-methylsulfonylbenzenesulfonamide Chemical compound ClC1=C(C=CC=C1)CONS(=O)(=O)C1=C(C=CC=C1)S(=O)(=O)C OIFXFVKTGVOGRR-UHFFFAOYSA-N 0.000 claims 1
- HCHFFKOYFAKLNI-UHFFFAOYSA-N N-[(2-chlorophenyl)methoxy]-3-methylsulfonylbenzenesulfonamide Chemical compound ClC1=C(C=CC=C1)CONS(=O)(=O)C1=CC(=CC=C1)S(=O)(=O)C HCHFFKOYFAKLNI-UHFFFAOYSA-N 0.000 claims 1
- AGWSDLVQBYOSRH-UHFFFAOYSA-N N-[(2-fluorophenyl)methoxy]-2-methylsulfonylbenzenesulfonamide Chemical compound FC1=C(C=CC=C1)CONS(=O)(=O)C1=C(C=CC=C1)S(=O)(=O)C AGWSDLVQBYOSRH-UHFFFAOYSA-N 0.000 claims 1
- DWVAHNXDQOFLOJ-UHFFFAOYSA-N N-[(2-methoxyphenyl)methoxy]-1-benzofuran-2-sulfonamide Chemical compound COC1=C(C=CC=C1)CONS(=O)(=O)C=1OC2=C(C=1)C=CC=C2 DWVAHNXDQOFLOJ-UHFFFAOYSA-N 0.000 claims 1
- LPXMJDLPKMKNAI-UHFFFAOYSA-N N-[(2-methylpropan-2-yl)oxy]-2-methylsulfonylbenzenesulfonamide Chemical compound C(C)(C)(C)ONS(=O)(=O)C1=C(C=CC=C1)S(=O)(=O)C LPXMJDLPKMKNAI-UHFFFAOYSA-N 0.000 claims 1
- AMTFLQIAXGTEMJ-UHFFFAOYSA-N N-[(3,5-dibromo-2-hydroxyphenyl)methoxy]-2-methylsulfonylbenzenesulfonamide Chemical compound BrC=1C(=C(C=C(C=1)Br)CONS(=O)(=O)C1=C(C=CC=C1)S(=O)(=O)C)O AMTFLQIAXGTEMJ-UHFFFAOYSA-N 0.000 claims 1
- YBNNWUQGDWJSOQ-UHFFFAOYSA-N N-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]-1-benzofuran-2-sulfonamide Chemical compound CC1=C(CONS(=O)(=O)C2=CC3=CC=CC=C3O2)C(C)=NO1 YBNNWUQGDWJSOQ-UHFFFAOYSA-N 0.000 claims 1
- ZHIBTIUFIVPERB-UHFFFAOYSA-N N-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]-3-methylsulfonylbenzenesulfonamide Chemical compound CC1=C(CONS(=O)(=O)C2=CC(=CC=C2)S(C)(=O)=O)C(C)=NO1 ZHIBTIUFIVPERB-UHFFFAOYSA-N 0.000 claims 1
- UAUPXBKYBMDOSL-UHFFFAOYSA-N N-[(3-chlorophenyl)methoxy]-2-methylsulfonylbenzenesulfonamide Chemical compound ClC=1C=C(C=CC=1)CONS(=O)(=O)C1=C(C=CC=C1)S(=O)(=O)C UAUPXBKYBMDOSL-UHFFFAOYSA-N 0.000 claims 1
- BYDDNKUHAMFBJN-UHFFFAOYSA-N N-[(3-fluorophenyl)methoxy]-2-methylsulfonylbenzenesulfonamide Chemical compound FC=1C=C(C=CC=1)CONS(=O)(=O)C1=C(C=CC=C1)S(=O)(=O)C BYDDNKUHAMFBJN-UHFFFAOYSA-N 0.000 claims 1
- VSMHMNVPURCJPF-UHFFFAOYSA-N N-[(3-methoxyphenyl)methoxy]-1-benzofuran-2-sulfonamide Chemical compound COC=1C=C(C=CC=1)CONS(=O)(=O)C=1OC2=C(C=1)C=CC=C2 VSMHMNVPURCJPF-UHFFFAOYSA-N 0.000 claims 1
- XBEYTGGTRRMUNE-UHFFFAOYSA-N N-[(4-chlorophenyl)methoxy]-1-benzofuran-2-sulfonamide Chemical compound ClC1=CC=C(C=C1)CONS(=O)(=O)C=1OC2=C(C=1)C=CC=C2 XBEYTGGTRRMUNE-UHFFFAOYSA-N 0.000 claims 1
- GVKQJFXNTOIHNU-UHFFFAOYSA-N N-[(4-chlorophenyl)methoxy]-2-methylsulfonylbenzenesulfonamide Chemical compound ClC1=CC=C(C=C1)CONS(=O)(=O)C1=C(C=CC=C1)S(=O)(=O)C GVKQJFXNTOIHNU-UHFFFAOYSA-N 0.000 claims 1
- QBLLZSVIYNHTKH-UHFFFAOYSA-N N-[(4-chlorophenyl)methoxy]-3-methylsulfonylbenzenesulfonamide Chemical compound ClC1=CC=C(C=C1)CONS(=O)(=O)C1=CC(=CC=C1)S(=O)(=O)C QBLLZSVIYNHTKH-UHFFFAOYSA-N 0.000 claims 1
- ACKUCLSWUVEGNH-UHFFFAOYSA-N N-[(4-fluorophenyl)methoxy]-1-benzofuran-2-sulfonamide Chemical compound FC1=CC=C(C=C1)CONS(=O)(=O)C=1OC2=C(C=1)C=CC=C2 ACKUCLSWUVEGNH-UHFFFAOYSA-N 0.000 claims 1
- DXBFIKWCNBUVQO-UHFFFAOYSA-N N-[(4-fluorophenyl)methoxy]-2-methylsulfonylbenzenesulfonamide Chemical compound CS(=O)(=O)c1ccccc1S(=O)(=O)NOCc1ccc(F)cc1 DXBFIKWCNBUVQO-UHFFFAOYSA-N 0.000 claims 1
- BXSYXKOUNDEIDN-UHFFFAOYSA-N N-[(4-fluorophenyl)methoxy]-3-methylsulfonylbenzenesulfonamide Chemical compound FC1=CC=C(C=C1)CONS(=O)(=O)C1=CC(=CC=C1)S(=O)(=O)C BXSYXKOUNDEIDN-UHFFFAOYSA-N 0.000 claims 1
- BJMVSMXOHKZOGM-UHFFFAOYSA-N N-[(4-hydroxyphenyl)methoxy]-2-methylsulfonylbenzenesulfonamide Chemical compound OC1=CC=C(C=C1)CONS(=O)(=O)C1=C(C=CC=C1)S(=O)(=O)C BJMVSMXOHKZOGM-UHFFFAOYSA-N 0.000 claims 1
- BGSXOXBRCHVXHG-UHFFFAOYSA-N N-[(4-methoxyphenyl)methoxy]-1-benzofuran-2-sulfonamide Chemical compound COC1=CC=C(C=C1)CONS(=O)(=O)C=1OC2=C(C=1)C=CC=C2 BGSXOXBRCHVXHG-UHFFFAOYSA-N 0.000 claims 1
- OMANQQBVCQYRLU-UHFFFAOYSA-N N-[(4-propan-2-ylphenyl)methoxy]-1-benzofuran-2-sulfonamide Chemical compound CC(C)C1=CC=C(C=C1)CONS(=O)(=O)C=1OC2=C(C=1)C=CC=C2 OMANQQBVCQYRLU-UHFFFAOYSA-N 0.000 claims 1
- BBUQXEVTQHFYGU-UHFFFAOYSA-N N-[(4-tert-butylphenyl)methoxy]-3-methylsulfonylbenzenesulfonamide Chemical compound C(C)(C)(C)C1=CC=C(C=C1)CONS(=O)(=O)C1=CC(=CC=C1)S(=O)(=O)C BBUQXEVTQHFYGU-UHFFFAOYSA-N 0.000 claims 1
- XTVPPNFZCDRAOW-UHFFFAOYSA-N N-[(5-methyl-1,2-oxazol-3-yl)methoxy]-1-benzofuran-2-sulfonamide Chemical compound CC1=CC(=NO1)CONS(=O)(=O)C=1OC2=C(C=1)C=CC=C2 XTVPPNFZCDRAOW-UHFFFAOYSA-N 0.000 claims 1
- FUTVQWWMRSJZOZ-UHFFFAOYSA-N N-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy]-1-benzofuran-2-sulfonamide Chemical compound CC1=C(CONS(=O)(=O)C2=CC3=CC=CC=C3O2)OC(=O)O1 FUTVQWWMRSJZOZ-UHFFFAOYSA-N 0.000 claims 1
- JWNTUPKDBMCVCH-UHFFFAOYSA-N N-[4-[[(3-methylsulfonylphenyl)sulfonylamino]oxymethyl]phenyl]acetamide Chemical compound CS(=O)(=O)C=1C=C(C=CC=1)S(=O)(=O)NOCC1=CC=C(C=C1)NC(C)=O JWNTUPKDBMCVCH-UHFFFAOYSA-N 0.000 claims 1
- WDOPWKOFYUXBJF-UHFFFAOYSA-N N-cyclopentyloxy-1-benzofuran-2-sulfonamide Chemical compound C1(CCCC1)ONS(=O)(=O)C=1OC2=C(C=1)C=CC=C2 WDOPWKOFYUXBJF-UHFFFAOYSA-N 0.000 claims 1
- ZHXKMZGWTOMGTK-UHFFFAOYSA-N N-cyclopentyloxy-2-methylsulfonylbenzenesulfonamide Chemical compound CS(=O)(=O)c1ccccc1S(=O)(=O)NOC1CCCC1 ZHXKMZGWTOMGTK-UHFFFAOYSA-N 0.000 claims 1
- MAUVBRFEASFKAF-UHFFFAOYSA-N N-cyclopentyloxy-3-methylsulfonylbenzenesulfonamide Chemical compound C1(CCCC1)ONS(=O)(=O)C1=CC(=CC=C1)S(=O)(=O)C MAUVBRFEASFKAF-UHFFFAOYSA-N 0.000 claims 1
- QJRYDODHBRFZFO-UHFFFAOYSA-N N-ethoxy-2-methylsulfonylbenzenesulfonamide Chemical compound C(C)ONS(=O)(=O)C1=C(C=CC=C1)S(=O)(=O)C QJRYDODHBRFZFO-UHFFFAOYSA-N 0.000 claims 1
- RNVITFMTRVIRGK-UHFFFAOYSA-N N-methoxy-2-methylsulfonylbenzenesulfonamide Chemical compound CS(=O)(=O)C1=C(C=CC=C1)S(=O)(=O)NOC RNVITFMTRVIRGK-UHFFFAOYSA-N 0.000 claims 1
- NJFAUPUUHANJCV-UHFFFAOYSA-N N-methoxy-3-methylsulfonylbenzenesulfonamide Chemical compound CS(=O)(=O)C=1C=C(C=CC=1)S(=O)(=O)NOC NJFAUPUUHANJCV-UHFFFAOYSA-N 0.000 claims 1
- QGXFSLMLBPYDLW-UHFFFAOYSA-N N-methoxy-5-(morpholine-4-carbonyl)thiophene-2-sulfonamide Chemical compound CONS(=O)(=O)C=1SC(=CC=1)C(=O)N1CCOCC1 QGXFSLMLBPYDLW-UHFFFAOYSA-N 0.000 claims 1
- HSFVXEXERZPHOR-UHFFFAOYSA-N N-phenylmethoxypyridine-2-sulfonamide Chemical compound C(C1=CC=CC=C1)ONS(=O)(=O)C1=NC=CC=C1 HSFVXEXERZPHOR-UHFFFAOYSA-N 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical group [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 claims 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000002785 azepinyl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- OUCLHJJQSXBXRU-UHFFFAOYSA-N n-(2-methoxyethyl)benzenesulfonamide Chemical compound COCCNS(=O)(=O)C1=CC=CC=C1 OUCLHJJQSXBXRU-UHFFFAOYSA-N 0.000 claims 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 229940049953 phenylacetate Drugs 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562243267P | 2015-10-19 | 2015-10-19 | |
| US62/243,267 | 2015-10-19 | ||
| PCT/US2016/057478 WO2017070084A1 (en) | 2015-10-19 | 2016-10-18 | N-hydroxylsulfonamide derivatives as nitroxyl donors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018537419A JP2018537419A (ja) | 2018-12-20 |
| JP2018537419A5 true JP2018537419A5 (cg-RX-API-DMAC7.html) | 2019-11-28 |
| JP6957459B2 JP6957459B2 (ja) | 2021-11-02 |
Family
ID=57223781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519918A Active JP6957459B2 (ja) | 2015-10-19 | 2016-10-18 | ニトロキシルドナーとしてのｎ−ヒドロキシルスルホンアミド誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10730828B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3365325A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6957459B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20180070672A (cg-RX-API-DMAC7.html) |
| CN (1) | CN108368038A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017070084A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3365328A1 (en) | 2015-10-19 | 2018-08-29 | Cardioxyl Pharmaceuticals, Inc. | Pyrazolone derivatives as nitroxyl donors |
| US10913728B2 (en) | 2016-07-28 | 2021-02-09 | The Johns Hopkins University | O-substituted hydroxamic acids |
| SG11201906145YA (en) | 2017-01-03 | 2019-08-27 | Cardioxyl Pharmaceuticals Inc | Method of administering nitroxyl donating compounds |
| JP2021523201A (ja) * | 2018-05-15 | 2021-09-02 | バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 神経線維感作に関連する疾患を治療するための１，３−チアゾール−２−イル置換ベンズアミド |
| WO2025043108A1 (en) * | 2023-08-23 | 2025-02-27 | Bristol -Myers S Quibb Company | Co-crystals of nitroxyl donating compounds |
| WO2025121401A1 (ja) * | 2023-12-06 | 2025-06-12 | 日産化学株式会社 | ピラゾール化合物及び有害生物防除剤 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE666766A (cg-RX-API-DMAC7.html) * | 1964-07-11 | |||
| EP0503838A3 (en) * | 1991-03-08 | 1992-10-07 | Merck & Co. Inc. | Heterocyclic compounds bearing acidic functional groups as angiotensin ii antagonists |
| JPH04321671A (ja) * | 1991-04-17 | 1992-11-11 | Mitsubishi Petrochem Co Ltd | カルバモイルトリアゾール誘導体およびそれを有効成分とする除草剤 |
| US5734081A (en) * | 1994-08-05 | 1998-03-31 | Warner-Lambert Company | Arylthio compounds |
| US6586617B1 (en) * | 1999-04-28 | 2003-07-01 | Sumitomo Chemical Takeda Agro Company, Limited | Sulfonamide derivatives |
| JP2001026506A (ja) * | 1999-04-28 | 2001-01-30 | Takeda Chem Ind Ltd | スルホンアミド誘導体 |
| US20040038947A1 (en) | 2002-06-14 | 2004-02-26 | The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services | Method of treating ischemia/reperfusion injury with nitroxyl donors |
| US6936639B2 (en) | 2002-08-21 | 2005-08-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nitroxyl progenitors in the treatment of heart failure |
| AU2005209843B2 (en) | 2004-01-30 | 2012-02-16 | The Johns Hopkins University | Nitroxyl progenitor compounds and methods of use |
| WO2007002444A1 (en) | 2005-06-23 | 2007-01-04 | Johns Hopkins University | Thiol-sensitive positive inotropes |
| EP2596785A1 (en) | 2006-03-17 | 2013-05-29 | Johns Hopkins University School of Medicine | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors |
| CA2648384A1 (en) | 2006-04-13 | 2007-10-25 | Wake Forest University Health Sciences | C-nitroso-derived nitroxyl donors |
| BRPI0817562A2 (pt) * | 2007-09-26 | 2017-05-02 | Cardioxyl Pharmaceuticals Inc | derivados de n-hidroxilsulfonamida como novos doadores de niltroxil fisiologicamente úteis |
| HUE030372T2 (en) | 2008-05-07 | 2017-05-29 | Cardioxyl Pharmaceuticals Inc | New nitroso compounds as nitroxyl donors and methods for their use |
| US20110160200A1 (en) | 2009-11-23 | 2011-06-30 | Cardioxyl Pharmaceuticals, Inc. | Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension |
| JP5826762B2 (ja) | 2009-12-07 | 2015-12-02 | ザ ジョンズ ホプキンス ユニバーシティ | Ｎ−アシルオキシスルホンアミドおよびｎ−ヒドロキシ−ｎ−アシルスルホンアミド誘導体 |
| CN105130855B (zh) | 2009-12-07 | 2018-05-25 | 约翰斯霍普金斯大学 | 二酰基化的羟基胺衍生物及其用途 |
| EP2776402B1 (en) | 2011-10-17 | 2017-07-26 | The Johns Hopkins University | Meldrum's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors |
| EP2914579A1 (en) | 2012-11-01 | 2015-09-09 | The Johns Hopkins University | Controlled hno release through intramolecular cyclization-elimination |
| EP3427728B1 (en) | 2013-01-18 | 2021-07-07 | Cardioxyl Pharmaceuticals, Inc. | Pharmaceutical compositions comprising nitroxyl donors |
| ES2734060T3 (es) | 2014-01-17 | 2019-12-04 | Cardioxyl Pharmaceuticals Inc | Donadores de nitroxilo de N-hidroximetanosulfonamida |
| EP3148983A1 (en) | 2014-05-27 | 2017-04-05 | The Johns Hopkins University | N-hydroxylamino-barbituric acid derivatives as nitroxyl donors |
| WO2015183839A1 (en) | 2014-05-27 | 2015-12-03 | Cardioxyl Pharmaceuticals, Inc. | Pyrazolone derivatives as nitroxyl donors |
| EP3313831B1 (en) | 2015-06-26 | 2021-03-10 | The Johns Hopkins University | N-substituted hydroxamic acids with carbon-based leaving groups as efficient hno donors and uses thereof |
| EP3365328A1 (en) | 2015-10-19 | 2018-08-29 | Cardioxyl Pharmaceuticals, Inc. | Pyrazolone derivatives as nitroxyl donors |
-
2016
- 2016-10-18 EP EP16790490.3A patent/EP3365325A1/en not_active Withdrawn
- 2016-10-18 KR KR1020187014120A patent/KR20180070672A/ko not_active Ceased
- 2016-10-18 JP JP2018519918A patent/JP6957459B2/ja active Active
- 2016-10-18 WO PCT/US2016/057478 patent/WO2017070084A1/en not_active Ceased
- 2016-10-18 CN CN201680072191.XA patent/CN108368038A/zh active Pending
- 2016-10-18 US US15/769,171 patent/US10730828B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018537419A5 (cg-RX-API-DMAC7.html) | ||
| RU2454415C9 (ru) | Производное индола | |
| CA2494695A1 (en) | 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors | |
| JP2004534035A5 (cg-RX-API-DMAC7.html) | ||
| RU2461551C2 (ru) | Азолкарбоксамидное соединение или его фармацевтически приемлемая соль | |
| KR101179087B1 (ko) | 인간 단백질 티로신 포스파타아제 억제제 및 이용 방법 | |
| JP2007523905A5 (cg-RX-API-DMAC7.html) | ||
| RU2006123559A (ru) | Биарилсульфонамиды в качестве ммр-ингибиторов | |
| RU2007107349A (ru) | Пиперазиновые производные, применение для лечения желудочно-кишечных расстройств | |
| JP2005533004A5 (cg-RX-API-DMAC7.html) | ||
| JP2010506825A5 (cg-RX-API-DMAC7.html) | ||
| RU2008117170A (ru) | Пиримидинамидные соединения как ингибиторы pgds | |
| CA2409697A1 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| JP2008500320A5 (cg-RX-API-DMAC7.html) | ||
| RU2006119623A (ru) | Аллостерические модуляторы метаботропных глутаматных рецепторов | |
| RU2011134631A (ru) | Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний | |
| RU2013120064A (ru) | Композиции и способы лечения глазного отека, неоваскуляризации и связанных с ними заболеваний | |
| JP2003534336A5 (cg-RX-API-DMAC7.html) | ||
| JP2010519181A5 (cg-RX-API-DMAC7.html) | ||
| JP2004517080A5 (cg-RX-API-DMAC7.html) | ||
| RU2001126559A (ru) | Активаторы глюкокиназы | |
| JP2007523142A5 (cg-RX-API-DMAC7.html) | ||
| AU2004240885A1 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type I | |
| JP2013506637A5 (cg-RX-API-DMAC7.html) | ||
| RU2009102516A (ru) | Ингибиторы протеинтирозинфосфатазы человека и способы их использования |